In patients with malignancies, contrast-enhanced abdominal CT (hereafter abdominal CT) plays an important role in detecting carcinoma recurrence and assessing treatment response. In this study, we aim to investigate whether such a "double low" dose CT is feasible in patients with liver metastases of colorectal cancer using a vendor-agnostic artificial intelligence-based noise reduction and contrast enhancement software.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Enrollment
176
Simultaneous reduction of both radiation dose and contrast media dose
CT with standard radiation dose and contrast media dose
Seoul National University Hospital
Seoul, South Korea
RECRUITINGlesion conspicuity on portal venous phase
qualitative analysis of lesion conspicuity on portal venous phase on five-point scale (higher score indicates better conspicuity). Lesion conspicuity is compared between the two arms.
Time frame: 6 months after primary study completion.
lesion conspicuity on arterial phase
qualitative analysis of lesion conspicuity on arterial phase on five-point scale (higher score indicates better conspicuity) Lesion conspicuity is compared between the two arms.
Time frame: 6 months after primary study completion.
lesion detectability
lesion detectability is compared between the two arms, compared with reference standard. Figure-of-merit was obtained.
Time frame: 12 months after primary study completion.
Radiation dose
Dose-length product (mGy\*cm) is compared between the two arms.
Time frame: 1 month after primary study completion
Contrast media (CM) dose
The amount of CM dose is compared between the two arms.
Time frame: 1 month after primary study completion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.